Efficacy of presurgical therapy with tislelizumab and axitinib to downsize local lesions in locally advanced and metastatic renal cell carcinoma: a single-institution experience with long-term follow-up.

ABSTRACT:

Background

Systemic therapy with or without surgery is recommended in advanced renal cell carcinoma (RCC). The potential benefits of tislelizumab and axitinib as presurgical therapy in advanced RCC remain unclear. This study aimed to preliminarily assess the efficacy of short-term presurgical tislelizumab and axitinib in downsizing local lesions and its long-term oncological outcome with or without nephrectomy in advanced RCC.

Methods

Data were prospectively collected from patients with advanced RCC who received tislelizumab and axitinib and were scheduled for deferred nephrectomy. Efficacy was evaluated by the remission of all tumor lesions using computed tomography (CT), and oncological outcomes were also reported.

Results

Between March 2021 and May 2022, 11 patient

SUBMITTER: Zhao Q 

PROVIDER: S-EPMC11986526 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature